

## H. Lundbeck A/S

Ottiliavej 9  
DK-2500 Valby, Copenhagen  
CVR number: 56759913

Tel +45 36 30 13 11  
Fax +45 36 43 82 62

E-mail investor@lundbeck.com  
www.lundbeck.com



## Corporate Release

25 March 2015

### **Lundbeck held its Annual General Meeting on 25 March 2015 at the company's registered office**

**Valby, Denmark, 25 March 2015** - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.

Håkan Björklund, Lars Rasmussen and Terrie Curran were re-elected, while Lene Skole, Jesper Ovesen and Lars Holmqvist were elected to the Board of Directors. Christian Dyvig, Thorleif Krarup and Melanie Lee did not stand for re-election. Immediately after the general meeting, the Board of Directors elected Håkan Björklund as Chairman and Lene Skole as Deputy Chairman of the Board of Directors.

The Board of Directors of Lundbeck will hereafter comprise:

- Håkan Björklund (Chairman)
- Lene Skole (Deputy Chairman)
- Lars Rasmussen
- Terrie Curran
- Jesper Ovesen
- Lars Holmqvist
- Mona Elisabeth Elster (employee representative)
- Jørn Møller Mayntzhusen (employee representative)
- Henrik Sindal Jensen (employee representative)

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Jesper Ovesen, Lars Rasmussen and Lars Holmqvist were elected as members of the Audit Committee. Håkan Björklund, Lene Skole and Terrie Curran were elected as members of the Remuneration Committee. Håkan Björklund and Lene Skole were elected as members of the Scientific Committee.

The General Meeting approved the remuneration for the Board of Directors for 2015.

The General Meeting approved a separate fixed monthly salary to the Chairman due to extended operational responsibilities.

The General Meeting approved not to pay-out dividend.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.



The General Meeting authorized the Board of Directors to increase the share capital by a nominal amount of up to DKK 100.000.000 with or without pre-emption rights for the existing shareholders for a period until 25 March 2020.

The proposal of the Board of Directors to adjust the company's "Remuneration guidelines for the Board of Directors and the Executive Management of H. Lundbeck A/S" was approved.

The proposal to give the Board of Directors authorization to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted.

The Chairman of the General Meeting was authorized to adopt the amendments and register with the Danish Business Authority.

No other business was handled at the Annual General Meeting.

The Board of Directors

### Lundbeck contacts

Investors:

Palle Holm Olesen  
Vice President, Investor Relations  
palo@lundbeck.com  
+45 36 43 24 26

Media:

Mads Kronborg  
Director, Media Relations  
mavk@lundbeck.com  
+45 36 43 30 00

### About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer's disease, bipolar disorder, depression/anxiety, epilepsy, Huntington's disease, Parkinson's disease, schizophrenia, stroke and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease – we call this Progress in Mind.

Read more at [www.lundbeck.com/global/about-us/progress-in-mind](http://www.lundbeck.com/global/about-us/progress-in-mind).

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more 100 countries. We have research centers in China, Denmark and the United States and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of approximately DKK 13.5 billion in 2014 (EUR 1.8 billion; USD 2.4 billion).

For additional information, we encourage you to visit our corporate site [www.lundbeck.com](http://www.lundbeck.com).